Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
Sponsor: AIO-Studien-gGmbH
This PHASE2 trial investigates BRAF V600 Mutation and BRAF V600E and is currently completed. AIO-Studien-gGmbH leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2
Status: Unknown → Completed
-
Jul 2025 — Nov 2025 [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Sep 2022 — Jul 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AIO-Studien-gGmbH
- Merck Serono GmbH, Germany
- Pierre Fabre Pharma GmbH
- Universitätsklinikum Hamburg-Eppendorf
For direct contact, visit the study record on ClinicalTrials.gov .